



Fax completed form to: (855) 840-1678
 If this is an URGENT request, please call (800) 882-4462
 (800.88.CIGNA)

Braftovi (encorafenib)

PHYSICIAN INFORMATION			PATIENT INFORMATION		
* Physician Name:			*Due to privacy regulations we will not be able to respond via fax with the outcome of our review unless all asterisked (*) items on this form are completed.*		
Specialty:	* DEA, NPI or TIN:				
Office Contact Person:			* Patient Name:		
Office Phone:			* Cigna ID:	* Date of Birth:	
Office Fax:			* Patient Street Address:		
Office Street Address:			City:	State:	Zip:
City:	State:	Zip:	Patient Phone:		
Urgency: <input type="checkbox"/> Standard <input type="checkbox"/> Urgent (In checking this box, I attest to the fact that applying the standard review time frame may seriously jeopardize the customer's life, health, or ability to regain maximum function)					
Medication Requested: <input type="checkbox"/> Braftovi 50mg <input type="checkbox"/> Braftovi 75mg ICD10:					
Dose:		Frequency of therapy:		Duration of therapy:	
Is the requested medication for a chronic or long-term condition for which the prescription medication may be necessary for the life of the patient? <input type="checkbox"/> Yes <input type="checkbox"/> No					
What is your patient's diagnosis? <input type="checkbox"/> melanoma <input type="checkbox"/> colorectal cancer (CRC) <input type="checkbox"/> other (please specify):					
Clinical Information (if melanoma) Does your patient have documented V600E or V600K mutation of the BRAF gene? Yes <input type="checkbox"/> No <input type="checkbox"/> (if melanoma) Does your patient have unresectable or metastatic disease? Yes <input type="checkbox"/> No <input type="checkbox"/> (if melanoma) Will the drug requested be given in combination with binimetinib(Mektovi)? Yes <input type="checkbox"/> No <input type="checkbox"/> (if CRC) Does your patient have a V600e mutation of the BRAF gene? Yes <input type="checkbox"/> No <input type="checkbox"/> (if CRC w/V600e) Does your patient have metastatic disease? Yes <input type="checkbox"/> No <input type="checkbox"/> (if CRC w/V600e) Will the drug requested be given in combination with cetuximab (Erbix) or Vectibix (panitumumab)? Yes <input type="checkbox"/> No <input type="checkbox"/> (if CRC) Does your patient have a V600 mutation of the BRAF gene? Yes <input type="checkbox"/> No <input type="checkbox"/> (if CRC) Does your patient have unresectable, advanced or metastatic disease? Yes <input type="checkbox"/> No <input type="checkbox"/> (if CRC) Is/Will the requested medication be(ing) used in combination with Mektovi (binimetinib) AND either Erbitux (cetuximab) or Vectibix (panitumumab)? Yes <input type="checkbox"/> No <input type="checkbox"/> (if CRC) Has your patient previously received any chemotherapy for this diagnosis? Yes <input type="checkbox"/> No <input type="checkbox"/> (if CRC) Has your patient previously been treated with either Erbitux (cetuximab) or Vectibix (panitumumab) for this diagnosis? Yes <input type="checkbox"/> No <input type="checkbox"/> (if CRC) Has your patient previously been treated with oxaliplatin-based therapy without irinotecan (Camptosar) for this diagnosis? Yes <input type="checkbox"/> No <input type="checkbox"/> (if CRC) Has your patient previously been treated with irinotecan (Camptosar)-based therapy without oxaliplatin for this diagnosis? Yes <input type="checkbox"/> No <input type="checkbox"/> (if CRC) Has your patient previously been treated with FOLFOXIRI (fluorouracil, 5-FU [Aduvax]; leucovorin; oxaliplatin; irinotecan [Camptosar]) regimen for this diagnosis? Yes <input type="checkbox"/> No <input type="checkbox"/> (if CRC) Has your patient previously been treated with a fluoropyrimidine (like capecitabine [Xeloda], floxuridine, or fluorouracil [Aduvax, 5-FU] without irinotecan (Camptosar) or oxaliplatin, followed by FOLFOX (fluorouracil [Aduvax, 5-FU]; leucovorin; oxaliplatin) with or without Avastin (bevacizumab) for this diagnosis? Yes <input type="checkbox"/> No <input type="checkbox"/> (if CRC) Has your patient previously been treated with a fluoropyrimidine (like capecitabine [Xeloda], floxuridine, or fluorouracil [Aduvax, 5-FU] without irinotecan (Camptosar) or oxaliplatin, followed by CapeOX (capecitabine [Xeloda] and oxaliplatin) with or without Avastin (bevacizumab) for this diagnosis? Yes <input type="checkbox"/> No <input type="checkbox"/>					

Additional pertinent information (including disease stage, prior therapy, performance status, and names/doses/admin schedule of any agents to be used concurrently):

Attestation: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan or insurer its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature: _____ **Date:** _____

Save Time! Submit Online at: www.covermyeds.com/main/prior-authorization-forms/cigna/ or via SureScripts in your EHR.

Our standard response time for prescription drug coverage requests is 5 business days. If your request is urgent, it is important that you call us to expedite the request. View our Prescription Drug List and Coverage Policies online at cigna.com.

v081020

"Cigna" is a registered service mark, and the "Tree of Life" logo is a service mark, of Cigna Intellectual Property, Inc., licensed for use by Cigna Corporation and its operating subsidiaries. All products and services are provided by or through such operating subsidiaries and not by Cigna Corporation. Such operating subsidiaries include, for example, Cigna Health and Life Insurance Company and Cigna Health Management, Inc. Address: Cigna Pharmacy Services, PO Box 42005, Phoenix AZ 85080-2005